Rational Design of a Combination Medication for the Treatment of Obesity
Open Access
Abstract
Existing obesity therapies are limited by safety concerns and modest efficacy reflecting a weight loss plateau. Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction. In vitro electrophysiologic experiments were conducted to determine the extent to which BUP+NAL stimulated hypothalamic pro‐opiomelanocortin (POMC) neurons in mouse brain. A subsequent study further characterized the effect of combination BUP+NAL treatment on food intake in lean and obese mice. Finally, a randomized, blinded, placebo‐controlled trial in obese adult subjects was conducted. Randomization included: BUP (300 mg) + NAL (50 mg), BUP (300 mg) + placebo (P), NAL (50 mg) + P or P+P for up to 24 weeks. BUP+NAL stimulated murine POMC neurons in vitro and caused a greater reduction in acute food intake than either monotherapy, an effect consistent with synergism. Combined BUP+NAL provided sustained weight loss without evidence of an efficacy plateau through 24 weeks of treatment. BUP+NAL completers diverged from NAL+P (P < 0.01) and P+P (P < 0.001) at week 16 and from BUP+P by week 24 (P < 0.05). The combination was also well tolerated. Translational studies indicated that BUP+NAL therapy produced synergistic weight loss which exceeded either BUP or NAL alone. These results supported the hypothesis that NAL, through blockade of β‐endorphin mediated POMC autoinhibition, prevents the classic weight loss plateau observed with monotherapies such as BUP. This novel treatment approach (BUP+NAL) holds promise for the treatment of obesity.Keywords
This publication has 42 references indexed in Scilit:
- Cause-Specific Excess Deaths Associated With Underweight, Overweight, and ObesityJAMA, 2007
- Prevalence of Overweight and Obesity in the United States, 1999-2004JAMA, 2006
- Anatomy and regulation of the central melanocortin systemNature Neuroscience, 2005
- Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J miceInternational Journal of Obesity, 2000
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997
- Strategies for Dealing with Multiple Treatment Comparisons in Confirmatory Clinical TrialsDrug Information Journal, 1993
- Regulation of Proopiomelanocortin Gene Expression in Rat Brain and Pituitary as Studied by In Situ HybridizationAnnals of the New York Academy of Sciences, 1993
- Opioids Hyperpolarize β-Endorphin Neurons via μ-Receptor Activation of a Potassium ConductanceNeuroendocrinology, 1990
- Anorectic and behavioural effects of bupropionGeneral Pharmacology: The Vascular System, 1988
- Suppression of appetitive behavior in the rat by naloxone: Lack of effect of prior morphine dependenceLife Sciences, 1979